Oral and Topical Janus Kinase Inhibitors in Patients With Cutaneous T-Cell Lymphoma: A Real-World Single-Center Experience

This study retrospectively examined the use of Janus kinase inhibitors (JAKi) in 26 patients with cutaneous T-cell lymphoma (CTCL) at a tertiary cancer center from 2011 to 2024. Among these, 6 patients received JAKi specifically for CTCL treatment, with 4 using oral ruxolitinib and 2 using topical ruxolitinib. Notably, one patient on oral treatment achieved a complete response for 3 years, and another showed reduced lesion size over 1 year. Additionally, 13 patients received JAKi for other conditions post-CTCL diagnosis, such as graft versus host disease (GvHD) and hemophagocytic lymphohistiocytosis. However, 5 out of 9 patients treated for GvHD experienced CTCL relapse within a median of 8 weeks after ruxolitinib exposure. The findings suggest potential benefits of JAKi in CTCL treatment but highlight the need for further research to understand the safety and implications of JAKi use in CTCL patients.